251. Efficacy of psychological interventions on psychological outcomes in coronary artery disease: systematic review and meta-analysis
- Author
-
Marta Redondo, Adrian V. Hernandez, Inés Magán, Rosa Jurado-Barba, Héctor Bueno, Laura Casado, Haley Barnum, Instituto de Salud Carlos III, AstraZeneca, Ministerio de Ciencia, Innovación y Universidades (España), Camilo José Cela University (España), Agency for Healthcare Research and Quality (Estados Unidos), Ministerio de Ciencia e Innovación (España), Fundación ProCNIC, Instituto de Salud Carlos III - ISCIII, Universidad Camilo José Cela (España), and Agency Health Care Research and Quality (United States)
- Subjects
medicine.medical_specialty ,Psychological intervention ,Coronary Artery Disease ,030204 cardiovascular system & hematology ,Anxiety ,Psychosocial Intervention ,law.invention ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Applied Psychology ,Depression (differential diagnoses) ,Cognitive Behavioral Therapy ,business.industry ,Depression ,medicine.disease ,Confidence interval ,Psychiatry and Mental health ,Strictly standardized mean difference ,Meta-analysis ,medicine.symptom ,business ,Stress, Psychological - Abstract
The benefits of cognitive-behavioral treatment (CBT) and positive psychology therapy (PPT) in patients with cardiovascular disease are still not well defined. We assessed the efficacy of CBT and PPT on psychological outcomes in coronary artery disease (CAD) patients. Randomized controlled trials evaluating CBT or PPT in CAD patients published until May 2018 were systematically analyzed. Primary outcomes were depression, stress, anxiety, anger, happiness, and vital satisfaction. Random effects meta-analyses using the inverse variance method were performed. Effects were expressed as standardized mean difference (SMD) or mean differences (MD) with their 95% confidence intervals (CIs); risk of bias was assessed with the Cochrane tool. Nineteen trials were included (n = 1956); sixteen evaluated CBT (n = 1732), and three PPT (n = 224). Compared with control groups, depressive symptoms (13 trials; SMD -0.80; 95% CI -1.33 to -0.26), and anxiety (11 trials; SMD -1.26; 95% CI -2.11 to -0.41) improved after the PI, and depression (6 trials; SMD -2.08; 95% CI -3.22 to -0.94), anxiety (5 trials; SMD -1.33; 95% CI -2.38 to -0.29), and stress (3 trials; SMD -3.72; 95% CI -5.91 to -1.52) improved at the end of follow-up. Vital satisfaction was significantly increased at follow-up (MD 1.30, 0.27, 2.33). Non-significant effects on secondary outcomes were found. Subgroup analyses were consistent with overall analyses. CBT and PPT improve several psychological outcomes in CAD patients. Depression and anxiety improved immediately after the intervention while stress and vital satisfaction improve in the mid-term. Future research should assess the individual role of CBT and PPT in CAD populations. Dr. Bueno receives research funding from the Instituto de Salud Carlos III, Spain (PIE16/00021 &PI17/01799), Astra-Zeneca, BMS, Janssen and Novartis; has received consulting fees from Astra-Zeneca, Bayer, BMS-Pfizer, Novartis; and speaking fees or support for attending scientific meetings from Astra-Zeneca, Bayer, BMS-Pfizer, Novartis, and MEDSCAPE-theheart.org. Dr. Jurado receives research funding from the Ministerio de Ciencia, Innovación y Universidades, Spain (PSI2015-68851-P). Dr. Magán, Dr. Jurado, Dr. Redondo and Dr. Bueno have received funding from Universidad Camilo José Cela, Madrid – Spain (2015-18). Dr. Hernandez receives funding from the Agency Health Care Research and Quality (AHRQ) (HHSA290201500012I). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). Sí
- Published
- 2020